Is concomitant statin therapy required when initiating a PCSK9 inhibitor?

Do You Need to Be on a Statin with a PCSK9 Inhibitor?

Yes, PCSK9 inhibitors should be added to maximally tolerated statin therapy, not used as monotherapy, according to current guidelines. 1, 2

Guideline-Based Recommendation

The 2018 AHA/ACC Cholesterol Guidelines and 2022 ACC Expert Consensus clearly establish that PCSK9 inhibitors are indicated as add-on therapy to maximally tolerated statin therapy plus ezetimibe in very high-risk ASCVD patients when LDL-C remains ≥70 mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100 mg/dL (≥2.6 mmol/L). 1, 2

The Stepwise Algorithm:

1. Start with high-intensity statin (aiming for ≥50% LDL-C reduction) 1
2. If LDL-C remains ≥70 mg/dL on maximally tolerated statin, add ezetimibe 1
3. If LDL-C still ≥70 mg/dL on statin + ezetimibe, then add PCSK9 inhibitor 1, 2

Why Statins Are Required

The major outcome trials (FOURIER, ODYSSEY OUTCOMES) that demonstrated cardiovascular benefit with PCSK9 inhibitors enrolled patients already on background statin therapy. 3 The guidelines explicitly state that "maximally tolerated LDL-C lowering therapy should include maximally tolerated statin therapy and ezetimibe" before considering PCSK9 inhibitors. 1

Recent meta-analysis data confirms that PCSK9 inhibitors added to statins reduce MI by 19% (RR 0.81) and stroke by 26% (RR 0.74), but these benefits were demonstrated on top of statin therapy. 4

The Exception: Statin Intolerance

If you are truly statin-intolerant (documented inability to tolerate any statin at any dose), PCSK9 inhibitors can be used without statins. 4, 5 However, this is the exception, not the rule. The 2022 ACC Expert Consensus addresses this scenario specifically, allowing PCSK9 inhibitors in "documented statin intolerance." 2

Critical Caveat About Statin Intolerance:

Real-world data shows that PCSK9 inhibitor effectiveness is attenuated without concomitant statin therapy. A 2026 registry study found that predictors of greater LDL-C reduction included statin co-therapy, and inclisiran showed particularly attenuated effectiveness without statins. 5 This suggests the biological synergy between statins (which upregulate LDL receptors) and PCSK9 inhibitors (which prevent LDL receptor degradation) is clinically meaningful.

Real-World Evidence

Multiple recent studies confirm this approach:

• A 2025 meta-analysis of post-PCI patients showed combination therapy (PCSK9i + statin) significantly reduced MACE by 39% (RR 0.61) compared to statin alone 6
• A 2024 systematic review in ACS patients demonstrated that PCSK9 inhibitors added to high-intensity or maximally tolerated statin therapy achieved mean LDL-C reductions of 44 mg/dL beyond statin alone 7

Bottom Line

Do not use PCSK9 inhibitors as monotherapy unless you have documented, true statin intolerance. The evidence base, guideline recommendations, and biological rationale all support using PCSK9 inhibitors as add-on therapy to maximally tolerated statins (ideally with ezetimibe as well) in very high-risk patients who remain above LDL-C goals. 1, 2

The only scenario where PCSK9 inhibitor monotherapy is reasonable is confirmed statin intolerance after attempting multiple statins at various doses, but even then, expect somewhat reduced effectiveness compared to combination therapy. 5